Le Lézard
Classified in: Ebola virus, Health
Subject: ACC

Meda Aktiebolag Successfully Amends MTN Terms and Conditions and Exercises Call Option



SOLNA, Sweden, Dec. 6, 2017 /PRNewswire/ --

Meda Aktiebolag has successfully amended the terms and conditions of two series of notes issued pursuant to its SEK 7,000,000,000 medium term notes programme and inserted an early redemption call option which it will exercise with immediate effect

Today, Meda Aktiebolag (the "Company") held two noteholders' meetings pursuant to the summons sent on 7 November 2017 to the noteholders of the:

(i) SE0005132180 ? STIBOR 3M +2.85% 2013/2018 notes (the "2018 Notes"); and

(ii) SE0005991635 ? STIBOR 3M +1.65% 2014/2019 notes (the "2019 Notes" and together, with the 2018 Notes, the "Notes"),

issued under the SEK 7,000,000,000 medium term notes programme of the Company originally established on 25 May 2012 (as updated on 31 July 2012, 12 May 2014 and 16 July 2015), for the purposes of approving an amendment to the terms and conditions of the Notes to insert an early redemption call option (the "Call Option").

A sufficient number of noteholders were present in order for each noteholders' meeting to be quorate and a requisite majority of the voting noteholders at each noteholders meeting voted in favour of approving the proposed amendment to the terms and conditions.

As at the date hereof, the terms and conditions of the Notes have been effectively amended and the Company has given notice to the noteholders of each series of Notes that it will exercise the Call Option in accordance with the amended terms and conditions.

For further information regarding the amended terms and conditions and the Call Option, please refer to Skandinaviska Enskilda Banken AB (publ) acting as Tabulation and Paying Agent.

The Tabulation and Paying Agent:

 

Skandinaviska Enskilda Banken AB (publ)
Stjärntorget 4
SE-106 40 Stockholm
Sweden
Tel: +46 (0)8 763 80 96
Email: sebtenderagent@seb.se
Attention: SEB Tender Agent


 

The Board of directors
Meda Aktiebolag

For further inquiries, please contact:

Melissa Trombetta,
Head of Global Investor Relations
Mylan NV.
Tel: +1(917)262-2958
Melissa.Trombetta@mylan.com

This is information that Meda Aktiebolag is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 12:45 noon CET on 6 December 2017.

Meda Aktiebolag is a leading international specialty pharma company. Meda's products are sold in more than 120 countries worldwide and the company is represented by its own organizations in close to 60 countries. Find out more, visit www.meda.se.

This information was brought to you by Cision http://news.cision.com
http://news.cision.com/meda/r/meda-aktiebolag-successfully-amends-mtn-terms-and-conditions-and-exercises-call-option,c2408816

The following files are available for download:

http://mb.cision.com/Main/357/2408816/763332.pdf

Press release (PDF)

 

SOURCE MEDA


These press releases may also interest you

8 déc 2017
Her Excellency the Right Honourable Julie Payette, Governor General of Canada, will present the Meritorious Service Decorations (Civil Division) to 42 recipients from various sectors across the country on Tuesday, December 12, 2017, at 10:30 a.m.,...

8 déc 2017
Restated segment financials As announced in April 2017, Ericsson will start to report financials according to its new segments as of the fourth quarter 2017. To facilitate year-on-year comparisons, Ericsson today discloses the restated financials...

7 déc 2017
In the search for drugs that are effective against Ebola virus, scientists from SRI International and Collaborations Pharmaceuticals, Inc., led a study that used machine learning methods to identify tilorone dihydrochloride as a potential new...

7 déc 2017
Replikins Ltd. this week reported to the Healthcare Emergency Management Program of Boston University School of Medicine a four-fold increase in gene Replikin Counts in Global MERS-CoV from 2008 to 2017 (p<0.001) ? the highest ever recorded on...

6 déc 2017
Meda Aktiebolag has successfully amended the terms and conditions of two series of notes issued pursuant to its SEK 7,000,000,000 medium term notes programme and inserted an early redemption call option which it will exercise with immediate effect...

6 déc 2017
NanoViricides, Inc. (the "Company") reports that it has begun initial safety and toxicology evaluation of its optimized nanoviricides® drug candidates developed against varicella-zoster virus (VZV), the shingles virus.  This study is an important...




News published on 6 december 2017 at 07:16 and distributed by: